ERBB2 and breast carcinoma: There were 12 primary breast cancer patients and 12 patients with metastatic disease who had completed trastuzumab therapy before venepuncture, and all were negative for HER2 amplification in cfDNA apart from 3 metastatic breast cancer patients who had RQ values of 3.71, 6.02 and 16.97 in cfDNA (Table 2).